The development of alpine tourism and the increasing trend towards adventure travel have made high mountain regions accessible not only to healthy people, but also to patients with cardiorespiratory diseases such as COPD. However, they are also more susceptible to altitude-related illnesses. Swiss doctors investigated whether prophylactic treatment with acetazolamide (AZA) changes the physical performance of COPD patients at high altitudes.
Publikation
- InFo PNEUMOLOGIE & ALLERGOLOGIE
Related Topics
You May Also Like
- Hand eczema: from diagnosis to treatment
Implementing sustainable, stage-appropriate measures
- Cystic fibrosis
Small spray – big footprint
- From symptom to diagnosis
Abdominal pain – Gastric outlet stenosis
- When the bones become more fragile: “Case Finding”
Fracture risk reduction in osteoporosis
- Biologics for plaque psoriasis
What increases the chance of a sustained remission?
- Findings from the ALS Symposium 2024 in Montreal
Current and future approaches in the treatment of amyotrophic lateral sclerosis (ALS)
- Pain and autism
Hurdles to pain treatment for autistic patients
- Long-COVID